Low-Dose Immunotherapy  (LDI)

LDI, developed by Ty Vincent MD, is a treatment modality expanded from low-dose Allergy Therapy (LDA), originally pioneered in the US by W.A. Shrader MD.

Over the course of the last three decades, chronic allergies and immunological disorders have increased dramatically and have currently reached epidemic proportions.  These illnesses cause a great deal of suffering for many millions of people and have become a burden on the healthcare system.

People who suffer from chronic illness have a poor quality of life and may struggle for years without a diagnosis, or may be misdiagnosed with some form of psychosomatic disorder or mental illness.

LDI is an extremely low dose immunotherapy that uses a broad mixture of allergens and antigens in a dilute form in order to stimulate an immune response.  This occurs via an increased production of T regulator cells thereby promoting the body’s innate ability to heal itself.

LDI is administered orally or via intra-cutaneous injection.

LDI is a safe and effective technique that can by applied in the treatment of a multitude of chronic illnesses that are often difficult to resolve such as:

  • Allergies
  • Asthma
  • Autoimmune disorders (systemic lupus & rheumatoid arthritis, Hashimoto’s)
  • Interstitial Cystitis
  • Chemical sensitivity
  • Fibromyalgia
  • Chronic Fatigue Syndrome
  • Lyme disease
  • Microbial infections
  • Complex Gastro-intestinal disorders (Irritable Bowel Syndrome, Chrohn’s Disease, Ulcerative Colitis)


In some cases, patients may experience a localized swelling at the injection site. There may also be some itching and redness.  Rarely swelling can occur beyond the injection site but this is a temporary reaction.

For some patients, there can be a flare of symptoms following their LDI treatment.  This is considered to be a temporary unmasking and is a good sign that the therapy is working.  Each treatment is carefully selected and tailored to the individual patient to minimize the occurrence of such flares.